Navigation Links
$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research
Date:7/22/2014

es may go awry.

(iii) Develop cellular and animal models that faithfully mimic human disorders. In contrast to researchers studying cancer or diabetes, researchers studying psychiatric disorders have been unable to identify animal models that correctly capture important biological aspects of the disorders and correctly predict which therapies will be effective in humans. Now, with growing knowledge of the genes underlying psychiatric disorders, Broad researchers plan to create cellular models in the laboratory and animal models that more faithfully match both the genetic variation and the biochemical processes seen in human patients. They plan to pioneer cutting-edge techniques such as genome editing, which allows them to precisely introduce any mutations they choose.

(iv) Develop chemicals to modulate biological pathways to serve as drug leads. The researchers plan to build on the existing therapeutic efforts within the Stanley Center and draw on the Broad's Therapeutics Platform – a technological powerhouse with the capacity to create and screen hundreds of thousands of compounds – to identify molecules that can powerfully and precisely influence specific biological pathways relevant to psychiatric disorders. They then plan to comprehensively investigate those chemicals' effects to determine which of them might serve as promising leads for drugs that could be safely and effectively used in humans.

"We're still at the beginning of the curve of translating the emerging genetics into actionable biology, but it's happening much faster than I thought it would," said Scolnick. "I'd be bold enough to say that in five years, all the drug companies that got out of psychiatric research will be getting back in. The coming decades of psychiatric research will yield new science and a needed parallel effort to increase resources for services that can help patients and their families."

About the Stanley Center for Psychiatr
'/>"/>

SOURCE Broad Institute
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Edico Genome Raises $10 Million in Series A Financing to Commercialize DRAGEN Chip to Overcome Sequencing Data Analysis Bottleneck
2. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
3. Columbia Engineering wins $3 million ARPA-E grant to raise efficiency, lower cost of power grid
4. Mice Model Market worth $1,819.9 Million by 2018
5. Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone
6. PCCI Collaborates With UTSW On Top National Research Grants Totaling Over $30 Million
7. BioLife Solutions Preliminary 2013 Revenue Grows to $9 Million
8. Star Scientific, Inc. Arranges a $15 Million Credit Facility
9. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
10. Curoverse Raises $1.5 Million to Build Open Source Platform for Genomic and Biomedical Big Data
11. CNTS Awarded $40 Million Contract Supporting U.S. Military Through Global Public Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... For the fifth time since 2006, ExakTime has been ... fastest-growing companies. , “We’re so proud that ExakTime’s rapid and ... ExakTime CEO Tony Pappas said. , ExakTime earned its ranking ... rate of 61 percent from 2010 to 2013 and by ... percent. , Pappas cited strong performance in the construction market ...
(Date:9/23/2014)... 23, 2014 News Facts ... devoted to genome-based research for human health and ... is taking a bite out of oral cancer with its ... India with the help of state-of-the-art ... Networks (DDN). , To fuel its cutting-edge cancer research, ...
(Date:9/23/2014)... September 23, 2014 Equashield ... Transfer     Devices  (CSTD) for hazardous ... MedFront Medical Technology Corporation.  Equashield,s leading CSTD has ... Taiwan , China ... continues to expand globally, and throughout the ...
(Date:9/23/2014)... Plymouth, MN (PRWEB) September 23, 2014 ... named NimbeLink, a developer of cellular modems ... a finalist in the Startup category for the ... will be held at the Minneapolis Convention Center ... Minnesota companies and individuals who have shown superior ...
Breaking Biology Technology:ExakTime Makes Inc. 5000 List for the Fifth Time 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3
... Simbionix,the world,s leading developer of medical simulation systems, ... a global collaboration,agreement. Simbionix will exclusively distribute, market, ... virtual reality hysteroscopy simulator. , ... simulators for minimal,invasive surgery. "This new agreement further ...
... Put in Place to Serve Future Requirements of Stem ... SIAL ) today announced the launch of an ... to its extensive portfolio of industry-leading products developed specifically ... over 1,100 unique and highly-focused products that are expected ...
... All amounts are in U.S. dollarsQUEBEC CITY, March 11 /PRNewswire-FirstCall/ - ... Company"), a global biopharmaceutical company focused on endocrinology and oncology, today ... full year ended December 31, 2008., 2008 Highlights, ... First patients treated with AEZS-108 for a Phase 2 trial in ...
Cached Biology Technology:Simbionix Increases Product Offerings for OB/GYN Physicians 2Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal 2Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal 3AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 2AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 3AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 4AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 5AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 6AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 7AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 8AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 9AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 10
(Date:9/22/2014)... September 23, 2014 A new American Cancer Society ... Assistance Program (SNAP), previously known as the food ... with income eligible non-participants. The authors say the ... at enhancing the dietary quality of SNAP participants. ... individuals and households with the resources to obtain ...
(Date:9/22/2014)... researchers are studying a potential new treatment that reverses ... which scars develop in the lungs and severely hamper ... which is delivered to lung tissue intravenously. In mouse ... fibrosis after several days. , The findings were ... Medicine . , "The mimic, when injected into the ...
(Date:9/22/2014)... genetic sequencing technologies continue to evolve rapidly, becoming part ... establish appropriate policies and regulatory frameworks to address potential ... policy issue of the Journal of Law, Medicine ... experts with the Center for Medical Ethics and Health ... the tools to jumpstart this process. , Experts ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... Director,s T-R01 Award , Speedier Lab Testing With Results ... associate professor of pharmacology at Weill Cornell Medical College, ... NIH Director,s Transformative R01 award from the National Institutes ... innovative protein recognition technologies that may some day speed ...
... Fisher, associate professor in the Fischell Department of Bioengineering, ... Research and Technology Review Day with a tissue engineering ... tissue for implantation. Fisher,s technology was one of ... faculty members and graduate students at the Professor Venture ...
... Researchers have shown how an experimental drug might restore ... by preventing short circuits caused when tiny "potassium channels" ... also might be developed as a treatment for multiple ... a common type of spinal cord trauma, called "compression" ...
Cached Biology News:Weill Cornell science briefs: November 2009 2Weill Cornell science briefs: November 2009 3Weill Cornell science briefs: November 2009 4Weill Cornell science briefs: November 2009 5Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3Drug studied as possible treatment for spinal injuries 2Drug studied as possible treatment for spinal injuries 3